Innate Historical Balance Sheet

IPHA Stock

USD 2.04 0.04 2.00%

Trend analysis of Innate Pharma balance sheet accounts such as Other Current Liabilities of 14.8 M or Total Current Liabilities of 48.6 M provides information on Innate Pharma's total assets, liabilities, and equity, which is the actual value of Innate Pharma to its prevalent stockholders. By breaking down trends over time using Innate Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Innate Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Innate Pharma is a good buy for the upcoming year.

Innate Pharma Inventory

(2.88 Million)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.

About Innate Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Innate Pharma at a specified time, usually calculated after every quarter, six months, or one year. Innate Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Innate Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Innate currently owns. An asset can also be divided into two categories, current and non-current.

Innate Pharma Balance Sheet Chart

At present, Innate Pharma's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 48.6 M, whereas Total Assets are forecasted to decline to about 188 M.

Short Long Term Debt Total Other Current Liab Total Current Liabilities Current Deferred Revenue Net Debt

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Innate Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Innate Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most accounts from Innate Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Innate Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.At present, Innate Pharma's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 48.6 M, whereas Total Assets are forecasted to decline to about 188 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	42.3M	39.9M	45.9M	48.2M
Total Assets	207.9M	184.2M	211.8M	188.0M

Short Long Term Debt Total Total Assets

Innate Pharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Net Receivables
Total Assets		0.12	0.79	0.9	0.86	0.77	0.8	-0.83	-0.32	0.76	0.92	0.87	0.39	0.89	0.62	0.56	0.4	0.7	0.04	0.57	0.94	0.76	0.95	0.01	0.61	0.55
Short Long Term Debt Total	0.12		-0.05	0.0	0.04	0.22	-0.38	0.33	-0.89	-0.16	0.0	0.19	0.58	0.01	0.64	0.72	-0.04	0.27	0.9	0.81	0.16	0.37	0.06	0.65	0.69	-0.19
Other Current Liab	0.79	-0.05		0.81	0.63	0.35	0.74	-0.63	-0.1	0.88	0.66	0.55	0.35	0.71	0.33	0.26	0.54	0.51	-0.03	0.32	0.78	0.35	0.84	-0.11	0.32	0.69
Total Current Liabilities	0.9	0.0	0.81		0.79	0.65	0.85	-0.72	-0.14	0.66	0.76	0.78	0.07	0.69	0.41	0.33	0.18	0.44	-0.08	0.4	0.84	0.62	0.86	0.03	0.4	0.79
Total Stockholder Equity	0.86	0.04	0.63	0.79		0.78	0.6	-0.77	-0.18	0.54	0.83	0.9	0.27	0.72	0.53	0.42	0.07	0.32	-0.15	0.51	0.65	0.72	0.73	-0.02	0.51	0.43
Property Plant And Equipment Net	0.77	0.22	0.35	0.65	0.78		0.49	-0.63	-0.37	0.39	0.74	0.85	0.24	0.62	0.67	0.61	-0.04	0.45	0.0	0.57	0.65	0.96	0.61	0.16	0.66	0.25
Current Deferred Revenue	0.8	-0.38	0.74	0.85	0.6	0.49		-0.86	0.19	0.78	0.78	0.58	-0.05	0.77	0.13	0.05	0.43	0.53	-0.35	0.04	0.81	0.42	0.84	-0.27	0.11	0.67
Net Debt	-0.83	0.33	-0.63	-0.72	-0.77	-0.63	-0.86		-0.13	-0.73	-0.94	-0.66	-0.14	-0.91	-0.29	-0.19	-0.41	-0.55	0.39	-0.14	-0.74	-0.54	-0.83	0.28	-0.26	-0.38
Retained Earnings	-0.32	-0.89	-0.1	-0.14	-0.18	-0.37	0.19	-0.13		-0.03	-0.17	-0.34	-0.6	-0.19	-0.8	-0.86	-0.1	-0.49	-0.84	-0.92	-0.37	-0.53	-0.27	-0.39	-0.83	0.06
Accounts Payable	0.76	-0.16	0.88	0.66	0.54	0.39	0.78	-0.73	-0.03		0.72	0.53	0.46	0.83	0.24	0.2	0.79	0.7	-0.13	0.21	0.8	0.33	0.82	-0.18	0.23	0.44
Cash	0.92	0.0	0.66	0.76	0.83	0.74	0.78	-0.94	-0.17	0.72		0.76	0.35	0.97	0.53	0.46	0.43	0.67	-0.09	0.43	0.84	0.7	0.9	-0.07	0.51	0.34
Non Current Assets Total	0.87	0.19	0.55	0.78	0.9	0.85	0.58	-0.66	-0.34	0.53	0.76		0.37	0.68	0.61	0.53	0.12	0.47	-0.05	0.58	0.73	0.8	0.68	0.17	0.59	0.34
Non Currrent Assets Other	0.39	0.58	0.35	0.07	0.27	0.24	-0.05	-0.14	-0.6	0.46	0.35	0.37		0.48	0.55	0.6	0.62	0.62	0.5	0.62	0.41	0.31	0.36	0.41	0.57	-0.24
Cash And Short Term Investments	0.89	0.01	0.71	0.69	0.72	0.62	0.77	-0.91	-0.19	0.83	0.97	0.68	0.48		0.49	0.44	0.65	0.79	-0.03	0.41	0.87	0.59	0.91	-0.09	0.48	0.28
Common Stock Total Equity	0.62	0.64	0.33	0.41	0.53	0.67	0.13	-0.29	-0.8	0.24	0.53	0.61	0.55	0.49		0.98	0.12	0.59	0.5	0.84	0.59	0.82	0.55	0.31	1.0	0.07
Common Stock Shares Outstanding	0.56	0.72	0.26	0.33	0.42	0.61	0.05	-0.19	-0.86	0.2	0.46	0.53	0.6	0.44	0.98		0.14	0.63	0.61	0.86	0.57	0.77	0.5	0.38	0.99	0.03
Short Term Investments	0.4	-0.04	0.54	0.18	0.07	-0.04	0.43	-0.41	-0.1	0.79	0.43	0.12	0.62	0.65	0.12	0.14		0.75	0.08	0.1	0.55	-0.03	0.52	-0.1	0.12	-0.01
Non Current Liabilities Total	0.7	0.27	0.51	0.44	0.32	0.45	0.53	-0.55	-0.49	0.7	0.67	0.47	0.62	0.79	0.59	0.63	0.75		0.33	0.51	0.85	0.52	0.76	0.03	0.59	0.14
Other Current Assets	0.04	0.9	-0.03	-0.08	-0.15	0.0	-0.35	0.39	-0.84	-0.13	-0.09	-0.05	0.5	-0.03	0.5	0.61	0.08	0.33		0.73	0.15	0.2	0.09	0.4	0.55	-0.07
Other Stockholder Equity	0.57	0.81	0.32	0.4	0.51	0.57	0.04	-0.14	-0.92	0.21	0.43	0.58	0.62	0.41	0.84	0.86	0.1	0.51	0.73		0.53	0.7	0.5	0.34	0.88	0.12
Total Liab	0.94	0.16	0.78	0.84	0.65	0.65	0.81	-0.74	-0.37	0.8	0.84	0.73	0.41	0.87	0.59	0.57	0.55	0.85	0.15	0.53		0.67	0.96	0.03	0.59	0.55
Property Plant And Equipment Gross	0.76	0.37	0.35	0.62	0.72	0.96	0.42	-0.54	-0.53	0.33	0.7	0.8	0.31	0.59	0.82	0.77	-0.03	0.52	0.2	0.7	0.67		0.63	0.22	0.81	0.24
Total Current Assets	0.95	0.06	0.84	0.86	0.73	0.61	0.84	-0.83	-0.27	0.82	0.9	0.68	0.36	0.91	0.55	0.5	0.52	0.76	0.09	0.5	0.96	0.63		-0.09	0.54	0.61
Short Term Debt	0.01	0.65	-0.11	0.03	-0.02	0.16	-0.27	0.28	-0.39	-0.18	-0.07	0.17	0.41	-0.09	0.31	0.38	-0.1	0.03	0.4	0.34	0.03	0.22	-0.09		0.33	-0.17
Common Stock	0.61	0.69	0.32	0.4	0.51	0.66	0.11	-0.26	-0.83	0.23	0.51	0.59	0.57	0.48	1.0	0.99	0.12	0.59	0.55	0.88	0.59	0.81	0.54	0.33		0.07
Net Receivables	0.55	-0.19	0.69	0.79	0.43	0.25	0.67	-0.38	0.06	0.44	0.34	0.34	-0.24	0.28	0.07	0.03	-0.01	0.14	-0.07	0.12	0.55	0.24	0.61	-0.17	0.07

Click cells to compare fundamentals

Innate Pharma Account Relationship Matchups

Innate Pharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	307.4M	267.5M	207.9M	184.2M	211.8M	188.0M
Short Long Term Debt Total	19.1M	44.3M	42.3M	39.9M	45.9M	48.2M
Other Current Liab	14.3M	14.4M	13.0M	15.1M	17.4M	14.8M
Total Current Liabilities	46.7M	79.9M	41.3M	39.6M	45.6M	48.6M
Total Stockholder Equity	156.0M	107.4M	54.2M	51.9M	59.7M	81.7M
Property Plant And Equipment Net	11.7M	10.2M	8.5M	6.3M	7.3M	7.9M
Current Deferred Revenue	12.5M	12.5M	6.6M	5.9M	6.7M	6.4M
Net Debt	(117.7M)	(59.5M)	(42.0M)	(30.7M)	(27.6M)	(29.0M)
Retained Earnings	(220.5M)	(272.2M)	(330.3M)	(336.9M)	(303.2M)	(288.0M)
Accounts Payable	20.7M	14.7M	13.7M	8.6M	9.8M	17.0M
Cash	136.8M	103.8M	84.2M	70.6M	81.2M	84.5M
Non Current Assets Total	134.1M	129.2M	68.0M	36.2M	41.6M	55.5M
Non Currrent Assets Other	30.1M	30.0M	14.2M	19.6M	22.6M	23.7M
Cash And Short Term Investments	151.6M	119.8M	101.5M	92.5M	106.3M	106.4M
Common Stock Shares Outstanding	78.9M	79.5M	79.6M	80.5M	92.5M	53.1M
Short Term Investments	14.8M	16.1M	17.3M	21.9M	19.7M	16.8M
Liabilities And Stockholders Equity	307.4M	267.5M	207.9M	184.2M	211.8M	188.0M
Non Current Liabilities Total	104.8M	80.2M	112.4M	92.7M	106.6M	57.7M
Other Current Assets	12.3M	17.6M	35.3M	40.3M	46.4M	48.7M
Other Stockholder Equity	372.1M	375.2M	379.6M	384.3M	441.9M	464.0M
Total Liab	151.4M	160.1M	153.7M	132.3M	152.1M	106.3M
Property Plant And Equipment Gross	11.7M	11.7M	10.2M	8.5M	9.8M	8.0M
Total Current Assets	173.3M	138.3M	139.8M	148.0M	170.2M	132.5M
Short Term Debt	2.1M	30.7M	2.1M	8.9M	10.3M	10.8M
Common Stock	4.0M	4.0M	4.0M	4.0M	4.7M	2.8M
Net Receivables	10.6M	846K	3.1M	15.2M	17.5M	21.7M
Accumulated Other Comprehensive Income	355K	456K	819K	495K	569.3K	597.7K
Inventory	1.0	(4.9M)	(2K)	(3.4M)	(3.0M)	(2.9M)
Intangible Assets	46.3M	44.2M	42.6M	416K	478.4K	454.5K
Other Liab	45.5M	87.8M	66.7M	72.2M	65.0M	74.7M
Net Tangible Assets	120.4M	109.7M	63.2M	52.6M	60.5M	84.3M
Long Term Debt	16.9M	13.5M	38.9M	30.6M	35.2M	37.0M
Capital Lease Obligations	3.5M	2.8M	2.1M	835K	751.5K	713.9K
Long Term Investments	38.9M	39.9M	35.1M	9.8M	8.8M	8.4M
Short Long Term Debt	2.1M	30.7M	1.3M	8.5M	9.7M	5.6M
Non Current Liabilities Other	44.9M	33.0M	53.0M	45.0M	51.8M	54.4M
Property Plant Equipment	11.7M	11.7M	10.2M	8.5M	9.8M	10.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:

How To Invest In Innate

Details

Is Innate Stock a good investment?

Details

What is Innate Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.75)

Earnings Share

(0.46)

Revenue Per Share

0.419

Quarterly Revenue Growth

(0.69)

Return On Assets

(0.14)

The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Innate Historical Balance Sheet

Innate Pharma Inventory

(2.88 Million)

About Innate Balance Sheet Analysis

Innate Pharma Balance Sheet Chart

Total Current Liabilities

Current Deferred Revenue

Net Debt

Innate Pharma balance sheet Correlations

Innate Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Innate Pharma balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Common Stock	+ 0.99	Common Stock Shares Outstanding
Common Stock Shares Outstanding	+ 0.98	Common Stock Total Equity
Cash And Short Term Investments	+ 0.97	Cash
Property Plant And Equipment Gross	+ 0.96	Property Plant And Equipment Net
Total Current Assets	+ 0.96	Total Liab

Cash	- 0.94	Net Debt
Other Stockholder Equity	- 0.92	Retained Earnings
Cash And Short Term Investments	- 0.91	Net Debt
Retained Earnings	- 0.89	Short Long Term Debt Total
Common Stock Shares Outstanding	- 0.86	Retained Earnings
Net Debt	- 0.86	Current Deferred Revenue